Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01390064 · ClinicalTrials.gov registry record · Phase 1
Vaccination of High Risk Breast Cancer Patients
A Phase 1 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01390064 is a Phase 1 study that has completed, run by University of Arkansas. The registered enrollment target is 6 participants.
The verdict
NCT01390064, a Phase 1 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Objective - Determine the safety and tolerability of a peptide mimotope-based vaccine upon immunization of breast cancer subjects.
Interventions
- BIOLOGICAL Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-07 |
| Est. Completion | 2019-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01390064
The ClinicalTrials.gov registry entry for NCT01390064 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG is the first listed.
NCT01390064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01390064 about?
NCT01390064 is a clinical study titled "Vaccination of High Risk Breast Cancer Patients". Objective - Determine the safety and tolerability of a peptide mimotope-based vaccine upon immunization of breast cancer subjects.
What is the current status of trial NCT01390064?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-07. Estimated completion is 2019-07.
What interventions are being tested in trial NCT01390064?
The interventions under investigation include: Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG (BIOLOGICAL).
Who is sponsoring clinical trial NCT01390064?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.